Researchers in America have started a clinical trial to test a ground breaking gene therapy which aims to treat hearing loss by restoring sound detecting cells that have been damaged by trauma to the inner ear. Nicola Robas, from our Biomedical Research team, tells us more about this exciting research
A team of researchers and clinicians at UCL’s Ear Institute and the Royal National Throat Nose and Ear Hospital are delighted to announce that the REGAIN trial is approaching its first anniversary and are continuing to recruit people with hearing loss to participate in a ground breaking clinical trial to test the safety and efficacy of a new drug that aims to treat sensorineural hearing loss. The criteria for eligibility to participate in the trial has recently been broadened to include participants with hearing loss of up to 20 years duration (see below for further information).
Medicines like aminoglycoside antibiotics or cisplatin are used to combat life-threatening infections and cancer, respectively, but their use may come at the price of someone’s hearing. Several treatments to prevent the loss of hearing caused by these medicines are currently being developed. Our Translational Research Manager, Dr Carina Santos, tells us more.
We fund research across the globe into treatments for hearing loss and tinnitus. One of our newest projects, at the Bionics Institute in Australia, is investigating if we can improve how well cochlear implants work using light.
A project based at Cincinnati Children’s Hospital in the US is using virtual reality technology to assess children’s hearing. Dr Hannah Stewart tells us how.
We're really proud of everyone who's a part of Action on Hearing Loss, and hope you'll feel inspired to become a part of our community.
We campaign for changes that make life better for people who are confronting deafness, tinnitus and hearing loss.